Patent: 10,184,001
✉ Email this page to a colleague
Summary for Patent: 10,184,001
Title: | Effector-deficient anti-CD32a antibodies |
Abstract: | Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders. |
Inventor(s): | Francis; John (Longwood, FL), Amirkhosravi; Ali (Longwood, FL), Meyer; Todd (Longwood, FL), Robles-Carrillo; Liza (Rockledge, FL) |
Assignee: | Adventist Health System/Sunbelt Inc. (Altamonte Springs, FL) |
Application Number: | 15/171,734 |
Patent Claims: | see list of patent claims |
Details for Patent 10,184,001
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2034-11-26 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | ⤷ Try a Trial | 2034-11-26 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |